LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254
CLXH254C12201
Phase 2 small_molecule active
Quick answer
LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254 for Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active